Coagulation factor VIIa Recombinant Human is a form of recombinant human coagulation Factor VII used to treat hemophilia A and B. NovoSeven is a vitamin K-dependent glycoprotein consisting of 406 amino acid residues.
- Mechanism
- Curator reviewed
NovoSeven activates the coagulation or clotting cascade by cleaving Factor IX and Factor X, which activates them and then leads to activation of thrombin and fibrin.
- Primary indication
- For treatment of hemorrhagic complications in hemophilia A and B.Curator reviewed · 12 structured indications
- Formula / weight
- C1972H3076N560O597S28 · 45079.1 Da
- First approval
- Canada, 2006 · United States, 2008 · European Union, 2016
- Also known as
- activated recombinant human factor VII · Coagulation factor VIIa · Coagulation factor VIIa (recombinant) · Coagulation factor VIIa (recombinant)-jncw · Eptacog alfa
- Code names
- LR769
- Brand names
Resolves to
Clinical / RWD
What you can answer from here — as of September 12, 2026
3Protein targetsEach mapped to UniProt, with action and pharmacological actionListed above
Which drugs share a target with Coagulation factor VIIa Recombinant Human, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account